Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Wockhardt share price gains 14% on DCGI approval for 2 new antibiotics

The new drugs will target superbug like Methicillin-resistant Staphylococcus aureus, which is a leading cause of rising antimicrobial resistance.

January 16, 2020 / 11:56 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Wockhardt share price gained 14 percent intraday on January 16 after the pharma company received Indian regulatory approval for its two new antibiotics.

The Drug Controller General of India (DCGI) approved EMROK (IV) and EMROK 0 (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections, and concurrent bacteraemia.

The new drug will target superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

"By virtue of its broad spectrum activity against widely prevalent pathogens, including MRSA, superior safety over the currently available anti-MRSA agents and its unique properties, I believe EMROK/EMROK-O has a strong potential to effectively address the unmet medical need of the clinicians in the country,” said Dr Habil Khorakiwala, founder-chairman Wockhardt Group.